The lessons of Vioxx--drug safety and sales.
Waxman
Henry A
HA
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D004341:Drug Evaluation / Q000331:legislation & jurisprudence / Q000592:standards; D004345:Drug Industry; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D040541:Marketing / Q000191:economics; D009203:Myocardial Infarction / Q000139:chemically induced*; D009288:Naproxen / Q000627:therapeutic use; D015871:Scientific Misconduct; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D009288:Naproxen